Chronic Obstructive Pulmonary Disease, COPD Clinical Trial
Official title:
Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease. A Clinical, Randomized, Controlled Study for Evaluation of Clinical and Economic Consequences of Monitoring Service
The aim of this study is to evaluate the effect of monitoring patients with chronic obstructive pulmonary disease (COPD) after a hospitalization for COPD exacerbation or pneumonia. The patients are randomized to receive either standard treatment and follow up, or standard treatment and follow up, plus tele monitoring of key clinical parameters and symptoms for six months.
Telemedicine is a relatively new approach for the management of chronic obstructive pulmonary
disease (COPD) disease. Telemedicine, for monitoring disease exacerbation, is the focus area
of our research. The patient monitoring offers the possibility of early initiation of
treatment of patients who has evidence of COPD exacerbation or pulmonary infection. The
self-monitoring of potential exacerbation is started after a hospitalization, and is done by
the patient on a daily (not on weekends) basis initially. After one month the monitoring is
made at least three times weekly during the rest of the intervention period of six months.
With the help of the monitoring equipment, the patient answers a short series of health
related questions, and makes simple measurements of oxygen saturation, heart rate, lung
function and weight. Data is sent to the hospital, and here the staff can assess the data and
respond to them the same day, with a phone call to the patient, if the patient's condition
has changed. The selected telemonitoring-equipment, consists of a monitoring systems for the
assessment of key clinical parameters and symptoms. All patients, in the intervention group
as well as in the control group, are trained in the use of a standardized self-treatment
plan. It is expected that the monitoring of symptoms and signs will support patient
empowerment.
The investigation is planned to assess the clinical and economic effects of the intervention.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00108823 -
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
|
Phase 3 | |
| Completed |
NCT03064113 -
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
| Completed |
NCT00496470 -
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
|
Phase 4 | |
| Completed |
NCT02442206 -
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
|
Phase 4 | |
| Completed |
NCT03095456 -
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
|
Phase 3 | |
| Completed |
NCT02449018 -
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
|
Phase 2 |